STOCK TITAN
  1. Home
  2. News
  3. CLPT

ClearPoint Neuro Inc - CLPT STOCK NEWS

Welcome to our dedicated news page for ClearPoint Neuro (Ticker: CLPT), a resource for investors and traders seeking the latest updates and insights on ClearPoint Neuro.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ClearPoint Neuro's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ClearPoint Neuro's position in the market.

News
ClearPoint Neuro Announces Initiation of Limited Market Release for the SmartFrame OR™ Stereotactic System
Rhea-AI Summary
ClearPoint Neuro has announced the initiation of Market Release for its SmartFrame OR™ Stereotactic System, expanding its portfolio to the operating room. The system allows for complete procedures in the OR, potentially increasing the company's annual clinical procedure volume by more than 10%. The SmartFrame OR is compatible with existing neurosurgical operating room equipment, with a full market release planned for the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
ClearPoint Neuro to Announce First Quarter 2024 Results May 7, 2024
Rhea-AI Summary
ClearPoint Neuro, Inc. (CLPT) will announce its first-quarter 2024 financial results on May 7, 2024. Investors can join the live broadcast review on the same day at 4:30 p.m. Eastern time. The Company offers precise navigation solutions for brain and spine therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
Rhea-AI Summary
ClearPoint Neuro congratulates AviadoBio on treating the first patient in the ASPIRE-FTD clinical trial evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations. The trial will use ClearPoint Navigation and SmartFlow Cannula for gene therapy administration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
News
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency
Rhea-AI Summary
ClearPoint Neuro, Inc. (CLPT) congratulates partner PTC Therapeutics on BLA submission for Upstaza™, a potential treatment for AADC Deficiency, a rare pediatric movement disorder. If approved by the FDA, Upstaza™ would be the first therapy for AADC Deficiency in the U.S., addressing significant developmental delays and autonomic symptoms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.27%
Tags
none
-
News
ClearPoint Neuro Reports Fourth Quarter and Full-Year 2023 Results
Rhea-AI Summary
ClearPoint Neuro, Inc. reported strong financial results for Q4 2023 and full-year 2023, with revenue reaching $6.8 million and $24.0 million respectively. The company achieved a 32% year-over-year increase in Q4 2023 revenue and a 17% increase for the full year. Biologics and drug delivery revenue saw a 49% increase to $13.6 million in 2023. ClearPoint Neuro also highlighted operational achievements, including FDA clearances, first-in-human cases, and completion of a public stock offering. The company reaffirmed its 2024 revenue guidance to be between $28.0 million and $32.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.51%
Tags
earnings
-
News
Journal of Neurosurgery Publication Demonstrates Distinct Advantages of ClearPoint Prism® Neuro Laser Therapy System
Rhea-AI Summary
ClearPoint Neuro Announces Preclinical Results of ClearPoint Prism Neuro Laser Therapy System, Along with FDA Cleared SmartFrame Array Software 1.2
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.58%
Tags
none
News
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024
Rhea-AI Summary
ClearPoint Neuro, Inc. (CLPT) will release its financial results for the 2023 fourth quarter and full year on March 12th. Investors can join the live broadcast review to be held at 4:30 p.m. Eastern time. The Company offers precise navigation to the brain and spine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.69%
Tags
earnings
-
News
ClearPoint Neuro Announces Pricing of Public Offering of 2,307,694 Shares of Common Stock
Rhea-AI Summary
ClearPoint Neuro, Inc. (CLPT) announces the pricing of its underwritten public offering of 2,307,694 shares of common stock at $6.50 per share, with an option for additional shares. The offering aims to raise funds for general corporate purposes, including research, acquisitions, or debt repayment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.23%
Tags
offering
-
News
ClearPoint Neuro Launches Proposed Public Offering of Common Stock
Rhea-AI Summary
ClearPoint Neuro, Inc. (CLPT) announced a proposed underwritten public offering of its common stock, with the potential for additional shares to be offered. The offering is subject to market conditions, with Lake Street Capital Markets, LLC acting as the book-running manager. The SEC declared the shelf registration statement effective in November 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.23%
Tags
offering
News
ClearPoint Neuro Announces FDA Clearance and First-in-Human Cases Performed with the New 2.2 Software Version and the Integrated Maestro Brain Model
Rhea-AI Summary
ClearPoint Neuro, Inc. announces FDA Clearance and first-in-human cases using ClearPoint 2.2 Software with Maestro Brain Modeling. A key validation study for ClearPoint Maestro® Brain Model published in NeuroImage. The company aims to offer precise navigation for brain and spine procedures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
clinical trial
Stock CLPT logo
ClearPoint Neuro Inc

Nasdaq:CLPT

CLPT Rankings

#3996 Ranked by Market Cap
#4617 Ranked by Stock Gains
N/A Ranked by Dividends

CLPT Stock Data

157.27M
24.73M
7.6%
29.16%
4.72%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
Solana Beach

About CLPT

we are a medical device company that develops and commercializes innovative platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging, or mri, guidance. since our inception in 1998, we have focused on research and product development in the field of interventional mri. from 1998 to 2002, we deployed significant resources to fund our efforts to develop the foundational capabilities for enabling mri-guided interventions and to build an intellectual property position. in 2003, our focus shifted to identifying and building out commercial applications for the technologies we developed in prior years. we have two product platforms. our clearpoint® system, which is in commercial use in the united states, is used to perform minimally invasive surgical procedures in the brain. our cleartrace system, which is still in development, will be used to perform minimally invasive surgical procedures in the heart. bot